Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Cdk5 drives formation of heterogeneous pancreatic neuroendocrine tumors.

ABSTRACT: Cdk5 drives formation of heterogeneous pancreatic neuroendocrine tumors.

PROVIDER: PRJNA736305 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR14765974.fastq.gz	Fastqsanger.gz
	SRR14765975.fastq.gz	Fastqsanger.gz
	SRR14765976.fastq.gz	Fastqsanger.gz
	SRR14765977.fastq.gz	Fastqsanger.gz
	SRR14765978.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 21

Similar Datasets

Cdk5 drives formation of heterogeneous pancreatic neuroendocrine tumors.

Project description:Pancreatic neuroendocrine tumors (PanNETs) are a heterogeneous population of neoplasms that arise from hormone-secreting islet cells of the pancreas and have increased markedly in incidence over the past four decades. Non-functional PanNETs, which occur more frequently than hormone-secreting tumors, are often not diagnosed until later stages of tumor development and have poorer prognoses. Development of successful therapeutics for PanNETs has been slow, partially due to a lack of diverse animal models for pre-clinical testing. Here, we report development of an inducible, conditional mouse model of PanNETs by using a bitransgenic system for regulated expression of the aberrant activator of Cdk5, p25, specifically in b-islet cells. This model produces a heterogeneous population of PanNETs that includes a subgroup of well-differentiated, non-functional tumors. The utility of this model is enhanced by ability to form tumor-derived allografts. Production of these tumors demonstrates the causative potential of aberrantly active Cdk5 for generation of PanNETs. Further, we show that human PanNETs express Cdk5 pathway components, are dependent on Cdk5 for growth, and share genetic and transcriptional overlap with the INS-p25OE model. This new model of PanNETs will facilitate molecular delineation of Cdk5-dependent PanNETs and the development of new targeted therapeutics.

2021-06-10 | GSE176448 | GEO

Cdk5 drives formation of heterogeneous pancreatic neuroendocrine tumors.

Project description: Not available

| S-EPMC8642406 | biostudies-literature

Proteotranscriptomic classification and characterization of pancreatic neuroendocrine neoplasms

Project description:Pancreatic neuroendocrine neoplasms (PNENs) are biologically and clinically heterogeneous neoplasms. We used quantitative global proteomic analysis on 40 PNENs to compliment paired transcriptome data.

2021-11-30 | PXD024175 | Pride

Proteomic profiling of corticotroph pituitary neuroendocrine tumors

Project description:Corticotroph pituitary neuroendocrine tumors (PitNETs) are heterogeneous sellar neoplasms with variable clinical manifestations and outcomes. This deposit comprises proteomic data generated as part of an integrative meta-analysis of corticotroph PitNETs, which included epigenomic, transcriptomic, and proteomic investigations. Proteomic profiling was performed on 39 internal tumor samples. These data were integrated with previously published external molecular datasets. The combined analyses defined four clinically relevant molecular subgroups of corticotroph PitNETs.

2026-07-02 | PXD073952 | Pride

Rapid and Selective Targeting of Heterogeneous Pancreatic Neuroendocrine Tumors.

Project description: Not available

| S-EPMC7139119 | biostudies-literature

LC-MS of Human Blood of Pancreatic neuroendocrine tumors

Project description:Pancreatic Neuroendocrine tumors are challenging to diagnose and often detected at advanced stages due to lack of specific and sensitive biomarkers. This study utilized proteomics as a valuable approach for cancer biomarker discovery, therefore, mass spectrometry-based proteomic profiling was conducted on plasma samples from 12 subjects (3 controls; 9 PanNET patients) to identify potential proteins capable of effectively distinguish PanNET from healthy controls. 13.2% of proteins were uniquely identified in PanNET, while 60% were commonly expressed in PanNET and controls. 17 proteins exhibiting significant differential expression between PanNET and controls were identified with downstream analysis.

2024-01-26 | PXD045045 | Pride

Global epigenomic profiling of corticotroph pituitary neuroendocrine tumors

Project description:Corticotroph pituitary neuroendocrine tumors (PitNETs) are heterogeneous sellar neoplasms with variable clinical manifestations and growth behaviour. In this study, epigenomic data was generated as part of an integrative meta-analysis of corticotroph PitNETs, which included epigenomic, transcriptomic, and proteomic investigations. This deposit comprises idat files of tumor samples and adenohypophysial non-neoplastic control samples. These data were integrated with previously published external molecular datasets. The combined analyses defined four clinically relevant molecular subgroups of corticotroph PitNETs.

2026-07-03 | E-MTAB-16589 | biostudies-arrayexpress

Genome-wide methylation profiling of sporadic Pancreatic Neuroendocrine Tumors

Project description:Pancreatic neuroendocrine tumors (PanNETs) account for 1-3% of all neoplasms of the pancreas. Epigenetic changes seem to be the main drivers of PanNET tumorigenesis. Indeed, the most frequent mutated genes in PanNETs are DAXX (Death domain associated protein 6), ATRX (Transcriptional Regulator ATRX) and MEN1 (menin 1), which are all involved in epigenetic regulation. The objective of the project is to study the epigenetic changes undergoing in PanNETs. Specifically, we aimed at investigating whether do exist biologically important epigenetic differences in PanNET, useful for a clinically relevant classification.

2022-11-30 | E-MTAB-11962 | biostudies-arrayexpress

Genome-wide methylation profiling of sporadic Pancreatic Neuroendocrine Tumors

2020-11-30 | E-MTAB-7924 | biostudies-arrayexpress

Genome-wide methylation profiling of sporadic Pancreatic Neuroendocrine Tumors

2022-11-30 | E-MTAB-11965 | biostudies-arrayexpress